MRNA

Moderna, Inc. NASDAQ

Healthcare ·Biotechnology ·US · modernatx.com

$45.37

After hrs $47.29 -0.02%

Mkt Cap $17.6B

52w Low $22.28 62.0% of range 52w High $59.55

50d MA $51.86 200d MA $35.56

P/E (TTM) -6.2x

EV/EBITDA -4.2x

P/B 2.0x

Debt/Equity 0.2x

ROE -32.6%

P/FCF -5.6x

RSI (14) —

ATR (14) —

Beta 1.34

50d MA $51.86

200d MA $35.56

Avg Volume 8.1M

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
May 1, 2026	BMO	-3.02	-3.40	-12.6%	45.94	+1.5%	-1.2%	—	—	—	—	—	—
Feb 13, 2026	BMO	-2.54	-2.11	+16.9%	40.11	+4.3%	+5.3%	+9.5%	+16.2%	+23.9%	+24.3%	+32.9%	—
Nov 6, 2025	BMO	-1.87	-0.51	+72.7%	23.56	+7.1%	+3.3%	+4.2%	+5.1%	+12.1%	+13.4%	+18.7%	—
Aug 1, 2025	BMO	-2.99	-2.13	+28.8%	29.56	-6.7%	-6.6%	-6.5%	-7.1%	-9.6%	-10.0%	-18.2%	—
May 1, 2025	BMO	-2.92	-2.52	+13.7%	28.54	-3.0%	-5.3%	-3.3%	-2.5%	-14.4%	-15.7%	-5.2%	—
Feb 14, 2025	BMO	-2.68	-2.50	+6.7%	31.92	-4.4%	+3.4%	+12.0%	+12.5%	+5.7%	+11.3%	+8.7%	—
Nov 7, 2024	BMO	-1.91	0.03	+101.6%	51.81	+9.2%	-3.0%	-9.6%	-17.5%	-16.1%	-18.7%	-11.9%	—
Aug 1, 2024	BMO	-3.35	-3.33	+0.6%	119.22	-16.5%	-21.0%	-27.4%	-29.8%	-31.0%	-31.6%	-38.8%	—
May 2, 2024	BMO	-3.56	-3.07	+13.8%	111.46	+3.1%	+12.7%	+12.1%	+9.6%	+8.6%	+9.4%	+32.6%	—
Feb 22, 2024	BMO	-0.97	0.55	+156.7%	87.59	+4.9%	+13.5%	+10.1%	+7.3%	+9.8%	+11.3%	+26.0%	—
Nov 2, 2023	BMO	-2.01	-1.39	+30.8%	76.20	-15.6%	-6.5%	+1.7%	-5.4%	-3.3%	-6.4%	+4.8%	—
Aug 3, 2023	BMO	-3.84	-3.62	+5.7%	110.22	-1.4%	-0.2%	-1.8%	-8.2%	-9.5%	-7.6%	-0.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 2	Barclays	Maintains	Equal Weight → Equal Weight	—	$50.03	$48.15	-3.8%	-1.7%	-2.5%	+0.2%	+4.1%	+2.5%
Feb 23	Piper Sandler	Maintains	Overweight → Overweight	—	$49.87	$48.70	-2.3%	+0.8%	+1.3%	+3.0%	+3.7%	+7.4%
Feb 17	Goldman Sachs	Maintains	Neutral → Neutral	—	$42.23	$42.28	+0.1%	+4.0%	+10.3%	+17.7%	+18.1%	+19.1%
Feb 17	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$42.23	$42.28	+0.1%	+4.0%	+10.3%	+17.7%	+18.1%	+19.1%
Feb 17	Evercore ISI	Maintains	In Line → In Line	—	$42.23	$42.28	+0.1%	+4.0%	+10.3%	+17.7%	+18.1%	+19.1%
Dec 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$29.63	$29.46	-0.6%	-0.6%	+1.0%	+0.9%	+3.0%	+4.5%
Nov 21	Piper Sandler	Maintains	Overweight → Overweight	—	$22.36	$22.39	+0.1%	+6.1%	+8.0%	+10.7%	+11.9%	+16.2%
Nov 21	Leerink Partners	Maintains	Underperform → Underperform	—	$22.36	$22.39	+0.1%	+6.1%	+8.0%	+10.7%	+11.9%	+16.2%
Nov 21	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$22.36	$22.39	+0.1%	+6.1%	+8.0%	+10.7%	+11.9%	+16.2%
Nov 10	BofA Securities	Maintains	Underperform → Underperform	—	$24.54	$24.75	+0.9%	+0.9%	+7.6%	+8.8%	+1.7%	+0.9%
Nov 7	Barclays	Maintains	Equal Weight → Equal Weight	—	$24.33	$23.87	-1.9%	+0.9%	+1.8%	+8.5%	+9.8%	+2.6%
Oct 23	Citigroup	Maintains	Neutral → Neutral	—	$26.85	$25.82	-3.8%	-2.2%	-0.4%	-0.7%	-5.6%	-8.0%
Oct 23	UBS	Maintains	Buy → Buy	—	$26.85	$25.82	-3.8%	-2.2%	-0.4%	-0.7%	-5.6%	-8.0%
Oct 23	JP Morgan	Maintains	Underweight → Underweight	—	$26.85	$25.82	-3.8%	-2.2%	-0.4%	-0.7%	-5.6%	-8.0%
Oct 20	Needham	Maintains	Hold → Hold	—	$26.01	$26.41	+1.5%	+4.7%	+5.7%	+3.2%	+0.9%	+2.8%
Oct 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$27.53	$27.78	+0.9%	-2.5%	-2.9%	-4.6%	+0.7%	-1.4%
Aug 22	Leerink Partners	Maintains	Underperform → Underperform	—	$26.22	$26.38	+0.6%	+3.4%	-3.3%	-5.7%	-4.3%	-6.7%
Aug 4	Barclays	Maintains	Equal Weight → Equal Weight	—	$27.61	$28.02	+1.5%	+0.1%	-0.5%	-3.3%	-3.6%	-5.4%
Jul 22	BofA Securities	Maintains	Underperform → Underperform	—	$30.97	$30.98	+0.0%	+5.7%	+11.9%	+9.8%	+10.3%	+9.5%
May 22	JP Morgan	Maintains	Underweight → Underweight	—	$25.80	$25.50	-1.2%	+3.6%	+1.8%	+3.7%	+1.0%	+4.4%
May 2	UBS	Maintains	Buy → Buy	—	$27.03	$27.74	+2.6%	+2.1%	+3.0%	-9.6%	-11.0%	-9.8%
May 2	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$27.03	$27.74	+2.6%	+2.1%	+3.0%	-9.6%	-11.0%	-9.8%
May 2	Evercore ISI	Maintains	In Line → In Line	—	$27.03	$27.74	+2.6%	+2.1%	+3.0%	-9.6%	-11.0%	-9.8%
May 2	Barclays	Maintains	Equal Weight → Equal Weight	—	$27.03	$27.74	+2.6%	+2.1%	+3.0%	-9.6%	-11.0%	-9.8%
Apr 9	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$24.64	$24.02	-2.5%	+8.2%	-0.6%	+6.3%	+8.8%	+6.5%
Mar 21	JP Morgan	Maintains	Underweight → Underweight	—	$32.45	$32.05	-1.2%	+0.6%	+5.3%	+4.3%	-3.0%	-1.0%
Feb 19	UBS	Maintains	Buy → Buy	—	$35.75	$35.11	-1.8%	+0.4%	-5.7%	-0.6%	-5.2%	-6.9%
Feb 18	Barclays	Downgrade	Overweight → Equal Weight	—	$32.99	$33.05	+0.2%	+8.4%	+8.8%	+2.2%	+7.7%	+2.8%
Feb 18	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$32.99	$33.05	+0.2%	+8.4%	+8.8%	+2.2%	+7.7%	+2.8%
Feb 11	BofA Securities	Maintains	Underperform → Underperform	—	$31.87	$31.52	-1.1%	-2.9%	-4.2%	+0.2%	+3.5%	+12.2%
Jan 27	Evercore ISI	Maintains	In Line → In Line	—	$41.41	$40.87	-1.3%	+0.6%	+8.5%	-1.7%	-0.9%	-4.8%
Jan 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$34.46	$35.18	+2.1%	+0.9%	-2.0%	-1.2%	+4.1%	+11.7%
Jan 8	UBS	Maintains	Buy → Buy	—	$47.53	$47.60	+0.1%	-9.2%	-11.1%	-26.0%	-27.5%	-26.8%
Dec 18	Argus	Downgrade	Buy → Hold	—	$40.76	$40.05	-1.7%	-5.9%	-2.9%	-3.4%	-2.9%	-1.2%
Nov 26	JP Morgan	Maintains	Underweight → Underweight	—	$43.66	$43.13	-1.2%	-3.7%	-0.6%	-1.4%	+1.4%	-2.5%
Nov 18	Piper Sandler	Maintains	Overweight → Overweight	—	$36.85	$38.31	+4.0%	+7.2%	+1.2%	+0.2%	+3.8%	+11.6%
Nov 18	HSBC	Upgrade	Hold → Buy	—	$36.85	$38.31	+4.0%	+7.2%	+1.2%	+0.2%	+3.8%	+11.6%
Nov 8	Barclays	Maintains	Overweight → Overweight	—	$50.28	$50.42	+0.3%	-6.9%	-15.0%	-13.5%	-16.2%	-20.9%
Nov 4	JP Morgan	Maintains	Underweight → Underweight	—	$54.63	$54.60	-0.1%	-2.0%	-2.5%	-5.2%	-8.0%	-14.3%
Oct 24	UBS	Maintains	Buy → Buy	—	$53.39	$53.39	+0.0%	-1.1%	-0.6%	+2.6%	+3.4%	+2.5%
Aug 15	JP Morgan	Maintains	Neutral → Neutral	—	$82.25	$83.65	+1.7%	+5.3%	+5.6%	+9.4%	+5.7%	+5.3%
Aug 6	Deutsche Bank	Upgrade	Sell → Hold	—	$83.75	$84.92	+1.4%	-1.7%	-2.6%	+0.7%	+1.4%	-2.9%
Aug 5	RBC Capital	Downgrade	Outperform → Sector Perform	—	$86.58	$80.37	-7.2%	-3.3%	-4.9%	-5.8%	-2.6%	-1.9%
Aug 2	Barclays	Maintains	Overweight → Overweight	—	$94.17	$91.17	-3.2%	-8.1%	-11.1%	-12.6%	-13.4%	-10.5%
Aug 2	Piper Sandler	Maintains	Overweight → Overweight	—	$94.17	$91.17	-3.2%	-8.1%	-11.1%	-12.6%	-13.4%	-10.5%
Aug 2	Goldman Sachs	Maintains	Buy → Buy	—	$94.17	$91.17	-3.2%	-8.1%	-11.1%	-12.6%	-13.4%	-10.5%
Aug 2	RBC Capital	Maintains	Outperform → Outperform	—	$94.17	$91.17	-3.2%	-8.1%	-11.1%	-12.6%	-13.4%	-10.5%
Jun 27	Evercore ISI	Maintains	In Line → In Line	—	$122.45	$121.90	-0.4%	-1.0%	-3.0%	-5.3%	-4.4%	-5.3%
Jun 27	Piper Sandler	Maintains	Overweight → Overweight	—	$122.45	$121.90	-0.4%	-1.0%	-3.0%	-5.3%	-4.4%	-5.3%
Jun 12	Oppenheimer	Maintains	Outperform → Outperform	—	$148.39	$150.00	+1.1%	-0.5%	-2.1%	-5.6%	-7.1%	-10.2%

Recent Filings

8-K · 1.01 !! High

Moderna, Inc. -- 8-K 1.01: Material Agreement

Moderna settled patent litigation with Arbutus Biopharma and Genevant Sciences, resolving all pending infringement disputes in U.S. courts effective March 3, 2026.

Mar 5

8-K

Moderna, Inc. -- 8-K Filing

Moderna reported $1.9 billion in 2024 revenue with a $2.8 billion net loss, while its U.S. influenza vaccine faced FDA rejection despite regulatory acceptance elsewhere, creating near-term headwinds.

Feb 13

8-K · 8.01 !! High

Moderna, Inc. -- 8-K 8.01: Material Event / Announcement

Moderna's investigational influenza vaccine mRNA-1010 received a Refusal-to-File letter from the FDA, halting regulatory review and delaying potential commercialization of this candidate program.

Feb 11

Data updated apr 26, 2026 1:16pm · Source: massive.com